OmniAb, Inc. (OABI)

4.4800 +0.0500 (+1.13%) At close: 04:00PM EDT

OmniAb, Inc.

5980 Horton Street
Suite 600
Emeryville, CA 94608
United States
510 250 7800
https://www.omniab.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 106

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Matthew W. Foehr	President, CEO & Director	967.72k	N/A	1973
Mr. Kurt A. Gustafson	Executive VP of Finance & CFO	558.48k	N/A	1968
Mr. Charles S. Berkman J.D.	Chief Legal Officer & Secretary	734.33k	N/A	1969
Ms. Cia McCaffrey	Vice President of People & Talent	N/A	N/A	N/A
Dr. Bill Harriman Ph.D.	Senior Vice President of Antibody Discovery	N/A	N/A	N/A
Ms. Marie-Cecile van de Lavoir D.V.M., Ph.D.	Senior Vice President of Technical Operations & Genetics	N/A	N/A	N/A
Dr. Christel Iffland Ph.D.	Senior Vice President of Antibody Technologies	N/A	N/A	N/A
Dr. Douglas S. Krafte Ph.D.	Senior VP of Ion Channels/Transporters & Icagen Ion Channel Technology Site Head	N/A	N/A	1958
Ms. Donna Ventura CPA	Senior Vice President of Corporate Controller	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.

Corporate governance

OmniAb, Inc.’s ISS governance QualityScore as of 1 April 2024 is 7. The pillar scores are Audit: 5; Board: 8; Shareholder rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.